Isomorphic Labs, the Alphabet spin-off founded by Google DeepMind chief Demis Hassabis, has raised $2.1 billion to push its AI drug design platform into the next phase. The message from investors is blunt: if this works, pharma could get its own OpenAI moment, only with fewer chatbots and a lot more lab coats. The new […]